Polyelectrolyte Microcapsules as Antigen Delivery Vehicles To Dendritic Cells: Uptake, Processing, and Cross-Presentation of Encapsulated Antigens

2009 ◽  
Vol 121 (45) ◽  
pp. 8637-8641 ◽  
Author(s):  
Stefaan De Koker ◽  
Bruno G. De Geest ◽  
Satwinder K. Singh ◽  
Riet De Rycke ◽  
Thomas Naessens ◽  
...  
2009 ◽  
Vol 48 (45) ◽  
pp. 8485-8489 ◽  
Author(s):  
Stefaan De Koker ◽  
Bruno G. De Geest ◽  
Satwinder K. Singh ◽  
Riet De Rycke ◽  
Thomas Naessens ◽  
...  

Blood ◽  
2012 ◽  
Vol 120 (10) ◽  
pp. 2011-2020 ◽  
Author(s):  
Bithi Chatterjee ◽  
Anna Smed-Sörensen ◽  
Lillian Cohn ◽  
Cécile Chalouni ◽  
Richard Vandlen ◽  
...  

Abstract Dendritic cells (DCs) can capture extracellular antigens and load resultant peptides on to MHC class I molecules, a process termed cross presentation. The mechanisms of cross presentation remain incompletely understood, particularly in primary human DCs. One unknown is the extent to which antigen delivery to distinct endocytic compartments determines cross presentation efficiency, possibly by influencing antigen egress to the cytosol. We addressed the problem directly and quantitatively by comparing the cross presentation of identical antigens conjugated with antibodies against different DC receptors that are targeted to early or late endosomes at distinct efficiencies. In human BDCA1+ and monocyte-derived DCs, CD40 and mannose receptor targeted antibody conjugates to early endosomes, whereas DEC205 targeted antigen primarily to late compartments. Surprisingly, the receptor least efficient at internalization, CD40, was the most efficient at cross presentation. This did not reflect DC activation by CD40, but rather its relatively poor uptake or intra-endosomal degradation compared with mannose receptor or DEC205. Thus, although both early and late endosomes appear to support cross presentation in human DCs, internalization efficiency, especially to late compartments, may be a negative predictor of activity when selecting receptors for vaccine development.


RSC Advances ◽  
2016 ◽  
Vol 6 (17) ◽  
pp. 13636-13643 ◽  
Author(s):  
Hui Wang ◽  
Jian Chen ◽  
Jiajun Ying ◽  
Yuhong Xu ◽  
Ruilong Sheng

Developing new therapeutic vaccines to promote antigen cross-presentation in antigen-presenting cells, especially dendritic cells, is regarded as a promising approach to prime antigen-specific T cell responses against tumor cells.


2013 ◽  
Vol 210 (5) ◽  
pp. 1049-1063 ◽  
Author(s):  
Lillian Cohn ◽  
Bithi Chatterjee ◽  
Filipp Esselborn ◽  
Anna Smed-Sörensen ◽  
Norihiro Nakamura ◽  
...  

Human BDCA3+ dendritic cells (DCs), the proposed equivalent to mouse CD8α+ DCs, are widely thought to cross present antigens on MHC class I (MHCI) molecules more efficiently than other DC populations. If true, it is unclear whether this reflects specialization for cross presentation or a generally enhanced ability to present antigens on MHCI. We compared presentation by BDCA3+ DCs with BDCA1+ DCs using a quantitative approach whereby antigens were targeted to distinct intracellular compartments by receptor-mediated internalization. As expected, BDCA3+ DCs were superior at cross presentation of antigens delivered to late endosomes and lysosomes by uptake of anti-DEC205 antibody conjugated to antigen. This difference may reflect a greater efficiency of antigen escape from BDCA3+ DC lysosomes. In contrast, if antigens were delivered to early endosomes through CD40 or CD11c, BDCA1+ DCs were as efficient at cross presentation as BDCA3+ DCs. Because BDCA3+ DCs and BDCA1+ DCs were also equivalent at presenting peptides and endogenously synthesized antigens, BDCA3+ DCs are not likely to possess mechanisms for cross presentation that are specific to this subset. Thus, multiple DC populations may be comparably effective at presenting exogenous antigens to CD8+ T cells as long as the antigen is delivered to early endocytic compartments.


Vaccine ◽  
2010 ◽  
Vol 28 (50) ◽  
pp. 7897-7906 ◽  
Author(s):  
Sachiko Hirosue ◽  
Iraklis C. Kourtis ◽  
André J. van der Vlies ◽  
Jeffrey A. Hubbell ◽  
Melody A. Swartz

2020 ◽  
Vol 28 ◽  
pp. 102234 ◽  
Author(s):  
Aya C. Taki ◽  
Jasmine E. Francis ◽  
Ivana Skakic ◽  
Chaitali Dekiwadia ◽  
Thomas R. McLean ◽  
...  

Nanoscale ◽  
2019 ◽  
Vol 11 (29) ◽  
pp. 13878-13884 ◽  
Author(s):  
Chaeyeon Lee ◽  
Leeja Jose ◽  
KyuHwan Shim ◽  
Seong Soo A. An ◽  
Sunah Jang ◽  
...  

We introduce virus-mimetic polymer nanoparticles as tumor antigen delivery vehicles to induce adjuvant-free cancer Ag specific-immune responses.


Blood ◽  
2012 ◽  
Vol 119 (10) ◽  
pp. 2284-2292 ◽  
Author(s):  
Gerty Schreibelt ◽  
Lieke J. J. Klinkenberg ◽  
Luis J. Cruz ◽  
Paul J. Tacken ◽  
Jurjen Tel ◽  
...  

Abstract CLEC9A is a recently discovered C-type lectin receptor involved in sensing necrotic cells. In humans, this receptor is selectively expressed by BDCA3+ myeloid dendritic cells (mDCs), which have been proposed to be the main human cross-presenting mDCs and may represent the human homologue of murine CD8+ DCs. In mice, it was demonstrated that antigens delivered with antibodies to CLEC9A are presented by CD8+ DCs to both CD4+ and CD8+ T cells and induce antitumor immunity in a melanoma model. Here we assessed the ability of CLEC9A to mediate antigen presentation by human BDCA3+ mDCs, which represent < 0.05% of peripheral blood leukocytes. We demonstrate that CLEC9A is only expressed on immature BDCA3+ mDCs and that cell surface expression is lost after TLR-mediated maturation. CLEC9A triggering via antibody binding rapidly induces receptor internalization but does not affect TLR-induced cytokine production or expression of costimulatory molecules. More importantly, antigens delivered via CLEC9A antibodies to BDCA3+ mDCs are presented by both MHC class I (cross-presentation) and MHC class II to antigen-specific T cells. We conclude that CLEC9A is a promising target for in vivo antigen delivery in humans to increase the efficiency of vaccines against infectious or malignant diseases.


Sign in / Sign up

Export Citation Format

Share Document